Clinical Trial: First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Primary Central Nervous System Lymphoma
Study Type: INTERVENTIONAL
Official Title: Exploration of the Efficacy and Safety of Orelabrutinib Combined With Rituximab and Methotrexate (ORM Regimen) in the First-line Treatment of Primary Central Nervous System Lymphoma
Brief Summary:
Exploring the efficacy and safety of first-line treatment of primary central nervous system lymphoma with the combination of orelabrutinib, rituximab and methotrexate (ORM regimen).
Read more